Suchergebnisse - "Imai, Michitaka"

PubPharm (158)

1

Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2024

von Rimini, M. | Stefanini, B. | Tada, T. | +75

2

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

enthalten in: Cancer reports (Hoboken, N.J.) | 2024

von Ohama, H. | Hiraoka, A. | Tada, T. | +42

3

Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older : Multicenter study

enthalten in: Hepatology research : the official journal of the Japan Society of Hepatology | 2024

von Hatanaka, T. | Kakizaki, S. | Hiraoka, A. | +45

4

Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2024

von Tada, T. | Kumada, T. | Hiraoka, A. | +42

5

α-FAtE : A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

enthalten in: International journal of cancer | 2024

von Rossari, F. | Tada, T. | Suda, G. | +70

6

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

enthalten in: Targeted oncology | 2024

von Camera, S. | Rimini, M. | Rossari, F. | +73

7

Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older : Multicenter study

enthalten in: Hepatology Research | 2024

von Hatanaka, T. | Kakizaki, S. | Hiraoka, A. | +44

8

Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients : A mixed-effects regression model approach

enthalten in: Cancer medicine | 2023

von Hatanaka, T. | Kakizaki, S. | Hiraoka, A. | +44

9

Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices

enthalten in: Journal of gastroenterology | 2023

von Tada, F. | Hiraoka, A. | Tada, T. | +41

10

Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab

enthalten in: Hepatology research : the official journal of the Japan Society of Hepatology | 2023

von Hiraoka, A. | Kumada, T. | Tada, T. | +40

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]